GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (FRA:354) » Definitions » Return-on-Tangible-Equity

Collegium Pharmaceutical (FRA:354) Return-on-Tangible-Equity : Negative Tangible Equity% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Collegium Pharmaceutical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Collegium Pharmaceutical's annualized net income for the quarter that ended in Sep. 2024 was €33.6 Mil. Collegium Pharmaceutical's average shareholder tangible equity for the quarter that ended in Sep. 2024 was €-512.2 Mil. Therefore, Collegium Pharmaceutical's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 was Negative Tangible Equity%.

The historical rank and industry rank for Collegium Pharmaceutical's Return-on-Tangible-Equity or its related term are showing as below:

FRA:354' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -86.45   Med: -63.21   Max: -43.17
Current: Negative Tangible Equity

During the past 11 years, Collegium Pharmaceutical's highest Return-on-Tangible-Equity was -43.17%. The lowest was -86.45%. And the median was -63.21%.

FRA:354's Return-on-Tangible-Equity is ranked better than
99.89% of 911 companies
in the Drug Manufacturers industry
Industry Median: 6.82 vs FRA:354: Negative Tangible Equity

Collegium Pharmaceutical Return-on-Tangible-Equity Historical Data

The historical data trend for Collegium Pharmaceutical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Return-on-Tangible-Equity Chart

Collegium Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.63 Negative Tangible Equity Negative Tangible Equity - Negative Tangible Equity

Collegium Pharmaceutical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Competitive Comparison of Collegium Pharmaceutical's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Collegium Pharmaceutical's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Return-on-Tangible-Equity falls into.



Collegium Pharmaceutical Return-on-Tangible-Equity Calculation

Collegium Pharmaceutical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=44.158/( (-477.967+-330.243 )/ 2 )
=44.158/-404.105
=Negative Tangible Equity %

Collegium Pharmaceutical's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=33.644/( (-250.783+-773.558)/ 2 )
=33.644/-512.1705
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Collegium Pharmaceutical  (FRA:354) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Collegium Pharmaceutical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Collegium Pharmaceutical Headlines

No Headlines